Skip to main content

Table 1 Baseline patients characteristics

From: Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)

Characteristics PC group (n = 34) VGD group (n = 34)
Age, years   
   Median 66 64
   Range (33-75) (39-79)
Sex, n (%)   
   Male 19 (56%) 28 (82%)
   Female 15 (44%) 6 (18%)
ECOG performance status, n (%)   
   0 12 (35%) 15 (44%)
   1 22 (65%) 19 (56%)
Histologic type, n (%)   
   Adenocarcinoma 26 (76%) 22 (65%)
   Squamous cell 5 (15%) 9 (26%)
   Other 3 (9%) 3 (9%)
Stage, n (%)   
   IIIB 3 (9%) 4 (12%)
   IV 31 (91%) 30 (88%)
Weight loss (from 6 months before enrolment, n (%)   
   <5% 29 (85%) 31 (91%)
   ≥5% 5 (15%) 3 (9%)
LDH concentration, n (%)   
   Normal 28 (82%) 28 (82%)
   Abnormal 6 (18%) 6 (18%)
  1. LDH, lactate dehydrogenase.